PortalPublikationenSusceptibility to cephalosporin combinations and aztreonam/a...

Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

Standard

Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. / Mischnik, Alexander; Baumert, Philipp; Hamprecht, Axel; Rohde, Anna; Peter, Silke; Feihl, Susanne; Knobloch, Johannes K.-M.; Gölz, Hanna; Kola, Axel; Obermann, Birgit; Querbach, Christiane; Willmann, Matthias; Gebhardt, Friedemann; Tacconelli, Evelina; Gastmeier, Petra; Seifert, Harald; Kern, Winfried V; DZIF-ATHOS Study Group .

in: INT J ANTIMICROB AG, Jahrgang 49, Nr. 2, 02.2017, S. 239-242.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Mischnik, A, Baumert, P, Hamprecht, A, Rohde, A, Peter, S, Feihl, S, Knobloch, JK-M, Gölz, H, Kola, A, Obermann, B, Querbach, C, Willmann, M, Gebhardt, F, Tacconelli, E, Gastmeier, P, Seifert, H, Kern, WV & DZIF-ATHOS Study Group 2017, 'Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission', INT J ANTIMICROB AG, Jg. 49, Nr. 2, S. 239-242. https://doi.org/10.1016/j.ijantimicag.2016.10.013

APA

Mischnik, A., Baumert, P., Hamprecht, A., Rohde, A., Peter, S., Feihl, S., Knobloch, J. K-M., Gölz, H., Kola, A., Obermann, B., Querbach, C., Willmann, M., Gebhardt, F., Tacconelli, E., Gastmeier, P., Seifert, H., Kern, W. V., & DZIF-ATHOS Study Group (2017). Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. INT J ANTIMICROB AG, 49(2), 239-242. https://doi.org/10.1016/j.ijantimicag.2016.10.013

Vancouver

Mischnik A, Baumert P, Hamprecht A, Rohde A, Peter S, Feihl S et al. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission. INT J ANTIMICROB AG. 2017 Feb;49(2):239-242. https://doi.org/10.1016/j.ijantimicag.2016.10.013

Bibtex

@article{7473859951664a4587124a6e1a7ae860,
title = "Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission",
abstract = "As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0.5-4 mg/L for cefpodoxime/clavulanic acid and 0.25-1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.",
author = "Alexander Mischnik and Philipp Baumert and Axel Hamprecht and Anna Rohde and Silke Peter and Susanne Feihl and Knobloch, {Johannes K.-M.} and Hanna G{\"o}lz and Axel Kola and Birgit Obermann and Christiane Querbach and Matthias Willmann and Friedemann Gebhardt and Evelina Tacconelli and Petra Gastmeier and Harald Seifert and Kern, {Winfried V} and {DZIF-ATHOS Study Group}",
note = "Copyright {\textcopyright} 2016. Published by Elsevier B.V.",
year = "2017",
month = feb,
doi = "10.1016/j.ijantimicag.2016.10.013",
language = "English",
volume = "49",
pages = "239--242",
journal = "INT J ANTIMICROB AG",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

AU - Mischnik, Alexander

AU - Baumert, Philipp

AU - Hamprecht, Axel

AU - Rohde, Anna

AU - Peter, Silke

AU - Feihl, Susanne

AU - Knobloch, Johannes K.-M.

AU - Gölz, Hanna

AU - Kola, Axel

AU - Obermann, Birgit

AU - Querbach, Christiane

AU - Willmann, Matthias

AU - Gebhardt, Friedemann

AU - Tacconelli, Evelina

AU - Gastmeier, Petra

AU - Seifert, Harald

AU - Kern, Winfried V

AU - DZIF-ATHOS Study Group

N1 - Copyright © 2016. Published by Elsevier B.V.

PY - 2017/2

Y1 - 2017/2

N2 - As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0.5-4 mg/L for cefpodoxime/clavulanic acid and 0.25-1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.

AB - As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0.5-4 mg/L for cefpodoxime/clavulanic acid and 0.25-1 mg/L for aztreonam/avibactam, depending on the underlying resistance mechanism and organism. Based on in vitro testing, β-lactam antibiotics play an important role in the treatment of infections due to β-lactamase-producing organisms.

U2 - 10.1016/j.ijantimicag.2016.10.013

DO - 10.1016/j.ijantimicag.2016.10.013

M3 - SCORING: Journal article

C2 - 27939093

VL - 49

SP - 239

EP - 242

JO - INT J ANTIMICROB AG

JF - INT J ANTIMICROB AG

SN - 0924-8579

IS - 2

ER -